BDI

Black Diamond Reports First Quarter 2024 Results And Declares Dividend

Retrieved on: 
Friday, May 3, 2024

CALGARY, Alberta, May 02, 2024 (GLOBE NEWSWIRE) -- Black Diamond Group Limited ("Black Diamond", the "Company" or "we"), (TSX:BDI), a leading provider of space rental and workforce accommodation solutions, today announced its operating and financial results for the three months ended March 31, 2024 (the "Quarter") compared with the three months ended March 31, 2023 (the "Comparative Quarter").

Key Points: 
  • CALGARY, Alberta, May 02, 2024 (GLOBE NEWSWIRE) -- Black Diamond Group Limited ("Black Diamond", the "Company" or "we"), (TSX:BDI), a leading provider of space rental and workforce accommodation solutions, today announced its operating and financial results for the three months ended March 31, 2024 (the "Quarter") compared with the three months ended March 31, 2023 (the "Comparative Quarter").
  • The Company’s consolidated contracted future rental revenue at the end of the Quarter grew 5% from the Comparative Quarter to $137.1 million.
  • LodgeLink net revenue of $2.6 million grew 18% from the Comparative Quarter on higher booking volumes than the Comparative Quarter.
  • Subsequent to the end of the Quarter, the Company declared a second quarter dividend of $0.03 payable on or about July 15, 2024 to shareholders of record on June 30, 2024.

Black Diamond Reports Strong Fourth Quarter and Year-End Results and Declares Dividend

Retrieved on: 
Thursday, February 29, 2024

Since re-instating the dividend in 2021, the Company has announced three dividend increases, with the most recent occurring in the fourth quarter of 2023.

Key Points: 
  • Since re-instating the dividend in 2021, the Company has announced three dividend increases, with the most recent occurring in the fourth quarter of 2023.
  • LodgeLink also reported 101,726 room nights sold in the Quarter, a 13% decrease from the Comparative Quarter.
  • Funds from Operations¹ of $30.1 million and Free Cashflow¹ of $20.5 million for the Quarter were up 43% and 68%, respectively from the Comparative Quarter.
  • The WFS segment also ended the Quarter with $34.6 million of contracted future rental revenue, a 56% increase from the Comparative Quarter.

Mindbreeze Positioned as a "Leader" in the IDC MarketScape: Worldwide Knowledge Discovery Software for Internal-Facing Use Cases

Retrieved on: 
Tuesday, February 6, 2024

Mindbreeze, a leading provider of appliances and cloud services in the domain of information insight, is named a Leader in the IDC MarketScape: Worldwide Knowledge Discovery Software for Internal-Facing Use Cases 2023–2024 Vendor Assessment (doc #US51175723, January 2024).

Key Points: 
  • Mindbreeze, a leading provider of appliances and cloud services in the domain of information insight, is named a Leader in the IDC MarketScape: Worldwide Knowledge Discovery Software for Internal-Facing Use Cases 2023–2024 Vendor Assessment (doc #US51175723, January 2024).
  • Moreover, “Mindbreeze Business Decision Insights (BDI) provides an insights-as-a-service ecosystem with targeted solutions for specific business processes and functional areas.
  • Mindbreeze also provides professional services to assist with customization as needed” (IDC MarketScape: Worldwide Knowledge Discovery Software for Internal-Facing Use Cases 2023–2024 Vendor Assessment (doc #US51175723, January 2024)).
  • "We are honored to be positioned as a Leader in the IDC MarketScape: Worldwide Knowledge Discovery Software for Internal-Facing Use Cases 2023–2024 Vendor Assessment," shares Daniel Fallmann, founder and CEO of Mindbreeze.

EQS-News: APEX Group: exceet expands Supervisory Board with appointment of former Salzgitter CEO Prof. Dr.-Ing. Heinz Jörg Fuhrmann

Retrieved on: 
Tuesday, January 30, 2024

APEX Group: exceet expands Supervisory Board with appointment of former Salzgitter CEO Prof. Dr.-Ing.

Key Points: 
  • APEX Group: exceet expands Supervisory Board with appointment of former Salzgitter CEO Prof. Dr.-Ing.
  • Prof. Fuhrmann (67) was elected as a new member of the Supervisory Board.
  • At its constituent meeting immediately following the General Meeting today, the Supervisory Board elected Prof. Fuhrmann as Deputy Chair of the Supervisory Board.
  • Together with the Chair of the Supervisory Board, Roland Lienau, and the other members of the Supervisory Board, Prof. Fuhrmann will make a valuable contribution to the company's growth strategy.

 Mindbreeze’s Four Trends 2024: Sharpening the View of the Future with AI and Insight Engines

Retrieved on: 
Tuesday, November 28, 2023

Read on to find out which four technology trends organizations should have on their radar in 2024 to get through times of uncertainty.

Key Points: 
  • Read on to find out which four technology trends organizations should have on their radar in 2024 to get through times of uncertainty.
  • Huge software suites that cover as many use cases as possible have an expiration date in their traditional form.
  • These smart applications are highly specialized AI technologies that automate activities, support decision-making, and optimize processes to improve productivity.
  • With the help of insight engines and RAGs, LLMs can quickly provide contextual and specific answers to internal queries.

Swing Therapeutics Announces Positive Results from Pivotal Phase 3 Trial of Stanza, a Digital Therapy for Fibromyalgia Symptoms

Retrieved on: 
Tuesday, November 14, 2023

Swing Therapeutics, a leading developer of digital therapies for chronic pain conditions, today announced the successful completion of and positive results from its pivotal Phase 3 PROSPER-FM trial on Stanza, a self-guided smartphone-based behavioral therapy for the treatment of fibromyalgia symptoms in adult patients.

Key Points: 
  • Swing Therapeutics, a leading developer of digital therapies for chronic pain conditions, today announced the successful completion of and positive results from its pivotal Phase 3 PROSPER-FM trial on Stanza, a self-guided smartphone-based behavioral therapy for the treatment of fibromyalgia symptoms in adult patients.
  • Results from this multi-center, randomized controlled trial (RCT) were presented at the American College of Rheumatology (ACR) 2023 annual meeting this week.
  • Swing received De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) for Stanza in May 2023, making it the first prescription digital therapeutic indicated for treating fibromyalgia symptoms.
  • It delivers acceptance and commitment therapy (ACT), a type of cognitive behavioral therapy (CBT) with proven efficacy in treating fibromyalgia and other chronic pain conditions.

North America - The Maintenance, Repair, and Overhaul (MRO) Distribution Market size to grow at a CAGR of 2.43% from 2022 to 2027| The increasing penetration of Industry 4.0 is a key factor driving market growth -Technavio

Retrieved on: 
Wednesday, November 8, 2023

The increasing penetration of Industry 4.0 is a key factor driving market growth.

Key Points: 
  • The increasing penetration of Industry 4.0 is a key factor driving market growth.
  • Automation is a key aspect of Industry 4.0 as it reduces human intervention and ensures higher throughput, efficiency, reliability, and safety.
  • As a result, the North American maintenance, repair, and overhaul secondary market is expected to benefit from the positive impact of Industry 4.0.
  • Hence, the adoption of Industrial 4.0 is expected to drive market growth during the forecast period.

Black Diamond Reports Strong Third Quarter 2023 Results and Increases Dividend

Retrieved on: 
Thursday, November 2, 2023

The Company’s consolidated contracted future rental revenue at the end of the Quarter was $128.6 million, up $43.7 million or 51% from the Comparative Quarter.

Key Points: 
  • The Company’s consolidated contracted future rental revenue at the end of the Quarter was $128.6 million, up $43.7 million or 51% from the Comparative Quarter.
  • Modular Space Solutions ("MSS") contracted future rental revenue for units on rent was $99.7 million at the end of the Quarter, up 54% from the Comparative Quarter.
  • MSS rental revenue for the Quarter was a fourteenth consecutive record high at $22.0 million and was up 19% from the Comparative Quarter.
  • WFS rental revenue and Adjusted EBITDA for the Quarter were $17.5 million and $21.8 million, up 35% and 49% respectively from the Comparative Quarter.

Black Diamond Group Limited Announces Third Quarter 2023 Results Conference Call

Retrieved on: 
Friday, October 6, 2023

CALGARY, Alberta, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Black Diamond Group Limited (“Black Diamond” or the "Company”) (TSX: BDI), a leading provider of space rental and workforce accommodation, today announced the timing of its 2023 third quarter earnings release and conference call/webcast.

Key Points: 
  • CALGARY, Alberta, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Black Diamond Group Limited (“Black Diamond” or the "Company”) (TSX: BDI), a leading provider of space rental and workforce accommodation, today announced the timing of its 2023 third quarter earnings release and conference call/webcast.
  • Black Diamond intends to release its 2023 third quarter results after markets close on Thursday, November 2, 2023, and hold a conference call and webcast at 9:00 a.m. MT (11:00 a.m.
  • CEO Trevor Haynes and CFO Toby LaBrie will discuss Black Diamond’s financial results for the quarter and then take questions from investors and analysts.
  • Please connect approximately 10 minutes prior to the beginning of the call and ask to join the Black Diamond Group conference call.

Small Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder

Retrieved on: 
Wednesday, September 27, 2023

This is impressive especially when combined with previously reported Phase IIa SPL026 efficacy data in MDD showing a rapid antidepressant effect and sustained remission to six months.

Key Points: 
  • This is impressive especially when combined with previously reported Phase IIa SPL026 efficacy data in MDD showing a rapid antidepressant effect and sustained remission to six months.
  • In the Phase I/IIa SPL026 study, patients were required to be withdrawn from SSRIs, which can be a disruptive experience.
  • Through the SPL026-SSRI drug interaction study, Small Pharma aimed to address this requirement, which could enable broader patient recruitment on future large-scale studies, and potentially accelerate the clinical development pathway.
  • Efficacy was assessed using the Montgomery-Asberg Depression Rating scale (MADRS) to measure any change in patients’ depression symptoms from baseline.